drugset / Trial / NCT01139788
A Study of LY2624587 in Patients With Advanced Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Study CXBA is a multicenter nonrandomized, dose escalation, open-label, Phase 1 study of intravenous LY2624587 in patients with advanced or metastatic cancer for which no treatment of higher priority exists.
Timeline
- Start
- 2010-06
- Primary completion
- 2011-11
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY2624587 | Unknown | — | Intravenous |